Personalis
Open
$5.52
Prev. Close
$5.52
High
$5.59
Low
$5.50
Market Snapshot
$447.57M
-5.5
-1.32
$84.61M
260
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 260 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
emptyResult
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 260 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Recently from Cashu
Personalis Revolutionizes Cancer Treatment with Advanced Personalized Genomics Solutions
Personalis Advances Cancer Management with Personalized Genomics Personalis, Inc., a prominent player in the field of advanced genomics based in Fremont, California, continues to make strides in cance…
Personalis Innovates Cancer Care with Advanced Genomic Profiling Solutions
Personalis Advances Cancer Management Through Innovative Genomic Profiling Personalis, Inc., a pioneer in advanced genomics based in Fremont, California, is at the forefront of transforming cancer man…
Personalis Showcases Precision Oncology Innovations at BTIG Conference 2025
Personalis Emphasizes Innovation in Precision Oncology at Upcoming Conference Personalis, Inc., a leading biotechnology firm based in Fremont, California, is poised to showcase its innovative advancem…
Personalis Advances Lung Cancer Detection with Ultra-Sensitive ctDNA Testing Breakthrough
Breakthrough in Early Lung Cancer Detection Using Ultra-Sensitive ctDNA Testing Personalis, Inc. is making waves in the oncology landscape through its collaboration with Professor Charles Swanton and…